---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-116578"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:36:32.764118+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NRx Pharmaceuticals closes $11M unsecured debt financing from Streeterville Capital for Phase 3 trials

## Summary
- Secured $11M unsecured note from Streeterville Capital; net proceeds ~$10M after $1M OID and fees.
- Note bears 9% interest, 18-month maturity; monthly redemptions up to $1M starting May 2023.
- Redemptions may be paid in cash or common stock at 85% of VWAP; Company must reserve 45M shares.
- Proceeds will fund Phase 3 trial of NRX-101 for suicidal bipolar depression and PTSD.
- Note includes participation right for Streeterville on future debt issuances and most-favored-nation clause.

## SEC filing metadata
- accession: 0001104659-22-116578
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.03, 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000110465922116578/0001104659-22-116578-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000110465922116578/tm2230161d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-116578
- JSON: https://secwatch.observer/filing/0001104659-22-116578.json
- Plain text: https://secwatch.observer/filing/0001104659-22-116578.txt

## Key facts
- Debt Financings
  NRX Pharmaceuticals, Inc. incurred loan of $11,020,000 million with Streeterville Capital, LLC at 9% interest rate maturing 18 months from the issuance date.
  - Instrument: loan
  - Principal: $11,020,000 million
  - Counterparty: Streeterville Capital, LLC
  - Rate: 9% interest rate
  - Maturity: 18 months from the issuance date
  - Event: incurrence
  source text: On November 4, 2022, NRx Pharmaceuticals, Inc. (“NRx” or the “Company”) entered into a Securities Purchase Agreement (“SPA”) with Streeterville Capital, LLC, a Utah limited liability company (“Lender”), and, pursuant to the SPA, issued to the Lender an unsecured promissory note with a face amount of $11,020,000 million (the “Note”) before an original issue discount of $1,000,000, which was deducted from the proceeds of the Note.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000110465922116578/0001104659-22-116578-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.